Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Lansoprazole Sulfide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.62 |
| ▸ | ATP4A known ✓ | P20648 | 1/20 | 0.62 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.62 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.62 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.62 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.62 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.62 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.62 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.62 |
| ▸ | ATP4B known ✓ | P51164 | 1/20 | 0.62 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.62 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 8/20 | 0.98 |
| ▸ | NPC1 | O15118 | 7/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lansoprazole Sulfide SCHEMBL106519 | 0.99 | RAB9A (1.00) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL30053816 | 0.99 | RAB9A (1.00) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL6948284 | 0.98 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1681186 | 0.98 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1681462 | 0.94 | RAB9A (0.90) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL8184520 | 0.93 | RAB9A (0.89) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Water SCHEMBL6737289 | 0.92 | RAB9A (0.83) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Water SCHEMBL6737292 | 0.92 | RAB9A (0.83) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29323856 | 0.92 | RAB9A (0.86) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6440543 | 0.91 | RAB9A (0.85) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308492-B1 | Process for preparing lansoprazole | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2016-09-14 | — | — | EP | disclosed |
| US-9346783-B2 | Method and apparatus for producing oxidized compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20140100370-A1 | METHOD AND APPARATUS FOR PRODUCING OXIDIZED COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8592598-B2 | Method of producing a crystal of an imidazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2264025-B1 | Method for producing lansoprazole | TAKEDA PHARMACEUTICAL (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-1790647-B1 | METHOD FOR PRODUCING OXIDIZED COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-20130012714-A1 | NOVEL SOLVATE OF DEXLANSOPRAZOLE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-01-10 | — | — | US | disclosed |
| EP-1337525-B8 | PROCESS FOR THE CRYSTALLIZATION OF (R)- OR (S)-LANSOPRAZOLE | TAKEDA PHARMACEUTICAL (JP) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011098938-A1 | NOVEL SOLVATE OF DEXLANSOPRAZOLE | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2011-08-18 | — | — | WO | disclosed |
| EP-2345650-A1 | Amorphous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as anti-ulcer agent | Takeda Pharmaceutical Company Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-1790647-A1 | METHOD AND APPARATUS FOR PRODUCING OXIDIZED COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1681056-A1 | Process for preparing lansoprazole | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2006-07-19 | — | — | EP | disclosed |
| EP-1476441-A1 | A METHOD OF ELIMINATING SULFONE ANALOG IN THE SYNTHESIS OF PYRIDINE-BENZIMIDAZOLE SULFOXIDES | Ulkar Kimya Sanayii Ve Ticaret A.S. (TR) | 2004-11-17 | — | — | EP | disclosed |
| US-20040049045-A1 | Process for the crystallization of (r)-or (s)-lansoprazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1337525-A1 | PROCESS FOR THE CRYSTALLIZATION OF (R)- OR (S)-LANSOPRAZOLE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| WO-2003062223-A1 | A METHOD OF ELIMINATING SULFONE ANALOG IN THE SYNTHESIS OF PYRIDINE-BENZIMIDAZOLE SULFOXIDES | ULKAR KIMYA SANAYII VE TICARET ANONIM SIRKETI (TR) | 2003-07-31 | — | — | WO | disclosed |
| EP-0944617-B1 | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002044167-A1 | PROCESS FOR THE CRYSTALLIZATION OF (R)- OR (S)-LANSOPRAZOLE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-06 | — | — | WO | disclosed |
| WO-2001021617-A1 | PROCESS FOR PREPARING SULFOXIDE COMPOUNDS | DAEWOONG PHARM CO., LTD. (KR) | 2001-03-29 | — | — | WO | disclosed |
| US-6002011-A | Crystals of benzimidazole derivatives and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100370-A1 | METHOD AND APPARATUS FOR PRODUCING OXIDIZED COMPOUND | AOX1, PPOX, SCO2 | ADORA3 4039/4885ATP4A 4023/4885DRD4 1420/4885 |
| US-20130012714-A1 | NOVEL SOLVATE OF DEXLANSOPRAZOLE | CYP2D6, CYP2S1, CYP2F1 | ADORA3 1222/4885ATP4A 1875/4885DRD4 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.